Tag - RPHM

Reneo Therapeutics

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.